Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.

CIBINQO (abrocitinib) is a prescription medicine to treat adults with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

ABOUT
CIBINQO
BEFORE &
AFTER
SAFETY /
SIDE EFFECTS
SAVINGS &
SUPPORT
TALK TO YOUR DOCTOR SHARE YOUR
EXPERIENCE

Please rotate your device to continue viewing this site.

down arrow 1
down arrow 1

ABOUT CIBINQO

​​​​​​​CIBINQO:

Not an injection or cream
100% steroid free
The latest eczema treatment from Pfizer

CIBINQO (si-BINK-oh) is a new type of eczema treatment—a JAK inhibitor

JAK inhibitors disrupt the way cells in your immune system respond to certain cytokines. Cytokines are proteins that play a role in your body's immune response. They may contribute to inflammation you see and feel on the surface of the skin with eczema.

It’s not currently known how inhibiting specific JAK proteins can affect eczema.

The CIBINQO clinical trials included over 1,600 people with moderate-to-severe eczema

Those studied were determined to have moderate-to-severe eczema based on itch and signs of eczema on their skin
Some people took only CIBINQO and some took a placebo (unmedicated treatment). In one study, people took either CIBINQO with topical steroids or placebo with topical steroids. People were able to use a moisturizer in the studies
Some studies focused on effectiveness and safety over 3 or 4 months, and measured skin improvement, skin clearance, and itch reduction
People who completed a short-term study were able to enter a long-term study focused on safety
While people 12 to 17 years old were included in some of the studies, CIBINQO is not approved for use in pediatric patients


100% steroid-free.
​​​​​​​​​​​​​​​​​​​​​Not an injection or cream. 
CIBINQO – one pill, once a day.
​​​​​​​

CIBINQO (si-BINK-oh) is a new type of eczema treatment—a JAK1 inhibitor

JAK1 inhibitors disrupt the way cells in your immune system respond to certain cytokines. Cytokines are key players in the immune response that may contribute to inflammation you see on the surface of the skin with eczema.

CIBINQO was studied in 4 clinical trials of over 2,800 people with moderate-to-severe eczema


  • Participants' eczema was classified as moderate-to-severe based on itch and signs of eczema on their skin
  • CIBINQO was used with and without topical treatment
  • Efficacy and safety were evaluated in 3 studies that lasted 12 or 16 weeks and measured skin improvement, skin clearance, and itch reduction. People who completed a study were able to enter a long-term study, which focused on safety
  • CIBINQO was studied in people 12 years and older, but is approved for people 18 years and older.

In studies of 778 people, results showed that CIBINQO delivered:
Results PROVED that CIBINQO delivered:
Results showed

In studies of 778 people, results showed that CIBINQO delivered:

clearer skin icon

More people saw 75% skin improvement with CIBINQO alone vs
placebo after just 3 months:

  • 42% taking CIBINQO 100 mg
  • 62% taking CIBINQO 200 mg
  • 11% taking placebo
fast itch reduction

More people felt itch reduction taking CIBINQO alone vs
placebo after just 2 weeks:

  • 11% taking CIBINQO 100 mg
  • 26% taking CIBINQO 200 mg
  • 2% taking placebo

The recommended dose of CIBINQO is 100 mg. If you do not achieve an adequate response with CIBINQO 100 mg after 3 months, your doctor may consider an increase to CIBINQO 200 mg. If an adequate response isn't seen with CIBINQO 200 mg, stop taking CIBINQO 200 mg.

CIBINQO™ (abrocitinib) pill bottle

The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatinine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count. These are not all of the possible side effects of CIBINQO. For more information, talk to your doctor or learn more about the Most Important Information about CIBINQO.

BEFORE & AFTER

Real people, real results

View photos below and see results that real people experienced in clinical trials.

In studies of 778 people, more people achieved clear or almost clear skin at 3 months with CIBINQO alone (26% taking 100 mg and 41% taking 200 mg) vs placebo (8%).

The recommended dose of CIBINQO is 100 mg. If you do not achieve an adequate response with CIBINQO 100 mg after 3 months, your doctor may consider an increase to CIBINQO 200 mg. If an adequate response isn't seen with CIBINQO 200 mg, stop taking CIBINQO 200 mg.

Photos of people treated with CIBINQO in a clinical trial. Individual results may vary. 

Photos of a patient's abdomen. Patient took CIBINQO along with over-the-counter moisturizer.
Not everyone will respond to treatment with CIBINQO.

Close-up photos of a patient's upper arm. Not everyone will respond to treatment with CIBINQO.

Close-up photos of a patient's abdomen. Not everyone will respond to treatment with CIBINQO.

Close-up photos of a patient's calf. Not everyone will respond to treatment with CIBINQO.

Photos of a patient's lower shin. Not everyone will respond to treatment with CIBINQO.

Photos of a patient's lower chest and abdomen. Patient took CIBINQO with topical steroid treatment and over-the-counter moisturizer. In a study of 837 people, more people taking CIBINQO with topical steroids and daily moisturizer achieved clear or almost clear skin at 3 months (36% on 100 mg and 47% on 200 mg) vs people taking placebo with topical steroids and daily moisturizer (14%). Not everyone will respond to treatment with CIBINQO.

  • before and after eczema on abdomen
    Photos of a patient's abdomen. Patient took CIBINQO along with over-the-counter moisturizer.
    Not everyone will respond to treatment with CIBINQO.
  • before and after eczema on upper arm
    Close-up photos of a patient's upper arm. Not everyone will respond to treatment with CIBINQO.
  • before and after eczema on abdomen 1
    Close-up photos of a patient's abdomen. Not everyone will respond to treatment with CIBINQO.
  • before and after eczema on calf
    Close-up photos of a patient's calf. Not everyone will respond to treatment with CIBINQO.
  • before and after eczema on lower shin
    Photos of a patient's lower shin. Not everyone will respond to treatment with CIBINQO.
  • before and after eczema on lower chest and abdomen
    Photos of a patient's lower chest and abdomen. Patient took CIBINQO with topical steroid treatment and over-the-counter moisturizer. In a study of 837 people, more people taking CIBINQO with topical steroids and daily moisturizer achieved clear or almost clear skin at 3 months (36% on 100 mg and 47% on 200 mg) vs people taking placebo with topical steroids and daily moisturizer (14%). Not everyone will respond to treatment with CIBINQO.

SAVINGS & SUPPORT

See how you could pay as little as $0*​​​​​​​

Pfizer Dermatology Patient Access Logo

Sign up for the Pfizer Dermatology Patient Access savings and support program for CIBINQO. Eligible patients may pay as little as $0 with the Copay Savings Card.* You can get started in one of two ways.

savings card

Download a
Copay Savings Card
and stay in the know
​​​​​​​

​​​​​​​Get a 
​​​​​​​Copay Savings Card
texted to you now

Did you receive a physical Copay Savings Card?

savings & support icon 2
A live Support Representative can help you understand coverage and explore financial assistance options. Call 1-833-956-DERM (1-833-956-3376) Mon-Fri, 8 AM-8 PM EST, or ask your doctor’s office.
interim care program icon
Pfizer Dermatology Patient Access can help if your insurance delays or denies coverage of CIBINQO. Eligible, commercially insured patients enrolled in the Interim Care program may receive CIBINQO for up to 2 years at no cost.

*Eligibility required. No membership fees. For CIBINQO, the maximum benefit per patient is $15,000 per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the copay card. Terms and conditions apply.

Mobile terms and conditions apply. Msg & data rates may apply. Msg frequency varies. Text HELP for info, STOP to opt out. Pfizer’s privacy policy can be found at Pfizer.com/privacy.

Interim Care Rx is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for CIBINQO™ (abrocitinib), and who experience a delay or denial in insurance coverage during the prior authorization or appeals process. Not available to patients covered under Medicaid, Medicare or other federal or state healthcare programs.​​​​​​​
Limits, terms, and conditions apply.

auto

TALK TO YOUR DOCTOR

Talk to your doctor about CIBINQO

Here are a few tips to help you have a productive appointment.

Jot down any questions you have about CIBINQO in advance, and remember to take notes while talking with your doctor.

For a telemedicine visit, make sure you’re in a well-lit area. This way you can take clear photos and your doctor can easily see the areas you need examined. Avoid things that could irritate your skin before your appointment or photo, like a hot shower.

Tell your doctor about symptoms like itch and how often your eczema flares. Also, describe your eczema routine, how other prescription treatments have been working for you, and your goals for treatment. 

Mention every medication you take, including for other conditions. It may help to take pictures of each label with your phone.

Jot down any questions you have about CIBINQO in advance, and remember to take notes while talking with your doctor.

For a telemedicine visit, make sure you’re in a well-lit area. This way you can take clear photos and your doctor can easily see the areas you need examined. Avoid things that could irritate your skin before your appointment or photo, like a hot shower.

Tell your doctor about symptoms like itch and how often your eczema flares. Also, describe your eczema routine, how other prescription treatments have been working for you, and your goals for treatment.

Mention every medication you take, including for other conditions. It may help to take pictures of each label with your phone.

Get our full guide for talking with your doctor

​​​​​​​Ready to start the conversation with your doctor? We have a guide to help you prepare.

Please enter email in the format of name@domain.com

You’re all set.

Keep an eye out for the guide in your inbox. (If  it doesn't arrive soon, remember to check  your promotions and other folders, just in case.)

SHARE YOUR EXPERIENCE

Already prescribed CIBINQO? Share your experience with us!

We'd love to hear from you. Call us or write a short note with your story. You can even send us photos. Tell us about your experience:​​​​​
  • Right before you started treatment
  • During treatment (for example, after 2 weeks)
  • Your results after 3 months
​​​​​​​Help others in the eczema community learn about treatment by hearing the experiences of real people like you.
By clicking on the email link or calling the phone number above, you are confirming that the information you will provide is correct.
If your story and/or photo(s) is selected, you may also be invited to participate in various public relations, marketing, and/or promotional activities on behalf of Pfizer. Please also note that patients who opt-in will be required to sign release authorization, including a HIPAA form, and provide consent for Pfizer to contact their physicians for additional background information and medical records.
To understand how Pfizer may use your personal data, please click here for the Pfizer Privacy Policy.

IMPORTANT SAFETY INFORMATION and Indication

CIBINQO may cause serious side effects, including:

Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have died from these infections. Your risk of developing shingles may increase while taking CIBINQO.

Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.

Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:

  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired

CIBINQO can make you more likely to get infections or worsen infections you have.

There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).

Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.

There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.

Some people taking CIBINQO have had major cardiovascular events.

Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:

  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • weakness in one part or on one side of your body
  • slurred speech
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.

Get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.

Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results. You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your doctor should do blood tests about 4 weeks after you start treatment and 4 weeks after any increase in dose to check blood cell counts and as often as needed for other laboratory tests.

During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.

Before taking CIBINQO, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have one that won't go away or keeps returning
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have had hepatitis B or hepatitis C 
  • live or have lived in certain areas (such as Ohio & Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
  • have had any type of cancer
  • have had blood clots in the veins of your legs or lungs
  • are a current or past smoker
  • have had a heart attack, other heart problems, or stroke
  • have kidney or liver problems
  • have abnormal blood tests (low platelet count or white blood cell count)
  • have any eye problems, including cataracts or retinal detachment
  • have recently received or are scheduled to receive any vaccinations. People who take CIBINQO should not receive live vaccines
  • are or plan to become pregnant. It is not known if CIBINQO will harm your unborn baby. Pfizer has a Pregnancy Exposure Registry for pregnant women who take CIBINQO to check your health and the health of your baby. If you are pregnant or become pregnant while taking CIBINQO, ask your healthcare provider how you can join this pregnancy registry, call 1-877-311-3770 or visit www.CIBINQOPregnancyRegistry.com to enroll
  • are breastfeeding or plan to breastfeed. It is not known if CIBINQO passes into your breast milk. You should not take CIBINQO while breastfeeding
  • are taking other medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. CIBINQO and other medicines may affect each other, causing side effects. Especially tell your healthcare provider if you take aspirin or any antiplatelet therapies. Ask your healthcare provider if you are unsure

The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatinine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.

CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.

Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.

These are not all of the possible side effects of CIBINQO.

What is CIBINQO?

CIBINQO is a prescription medicine to treat adults with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

It is not known if CIBINQO is safe and effective in children.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.

How to get Pfizer Rx Assistance 1

A personalized savings and support program

Learn more about financial assistance options and other resources by talking to a Patient Support Representative.

patient support representative

Call 1-833-956-DERM (1-833-956-3376)
Monday-Friday, 8:00 AM-8:00 PM ET

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only).
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

You are encouraged to report adverse events related to Pfizer products by calling
1-800-438-1985 (U.S. only).

If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

CIBINQO may cause serious side effects, including:

Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have died from these infections. Your risk of developing shingles may increase while taking CIBINQO.

Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.

Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:

  •  
  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired
  •  

CIBINQO can make you more likely to get infections or worsen infections you have.

There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).

Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.

There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.

Some people taking CIBINQO have had major cardiovascular events.

Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:

  •  
  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • weakness in one part or on one side of your body
  • slurred speech
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  •  

Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.

Get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.

Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results. You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your doctor should do blood tests about 4 weeks after you start treatment and 4 weeks after any increase in dose to check blood cell counts and as often as needed for other laboratory tests.

During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.

Before taking CIBINQO, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have one that won't go away or keeps returning
  • have diabetes, chronic lung disease, HIV, or a weak immune system 
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have had hepatitis B or hepatitis C
  • live or have lived in certain areas (such as Ohio & Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections 
  • have had any type of cancer
  • have had blood clots in the veins of your legs or lungs
  • are a current or past smoker
  • have had a heart attack, other heart problems, or stroke
  • have kidney or liver problems
  • have abnormal blood tests (low platelet count or white blood cell count)
  • have any eye problems, including cataracts or retinal detachment
  • have recently received or are scheduled to receive any vaccinations. People who take CIBINQO should not receive live vaccines
  • are or plan to become pregnant. It is not known if CIBINQO will harm your unborn baby. Pfizer has a Pregnancy Exposure Registry for pregnant women who take CIBINQO to check your health and the health of your baby. If you are pregnant or become pregnant while taking CIBINQO, ask your healthcare provider how you can join this pregnancy registry, call 1-877-311-3770 or visit www.CIBINQOPregnancyRegistry.com to enroll
  • are breastfeeding or plan to breastfeed. It is not known if CIBINQO passes into your breast milk. You should not take CIBINQO while breastfeeding
  • are taking other medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. CIBINQO and other medicines may affect each other, causing side effects. Especially tell your healthcare provider if you take aspirin or any antiplatelet therapies. Ask your healthcare provider if you are unsure



The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatinine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.

CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.

Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.

These are not all of the possible side effects of CIBINQO.

What is CIBINQO?

CIBINQO is a prescription medicine to treat adults with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

It is not known if CIBINQO is safe and effective in children.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.

Patients should always ask their doctors for medical advice about adverse events.

​​​​​​​This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for ​​​​​​​educational purposes only and is not intended to replace discussions with a healthcare provider.

CIBINQO (abrocitinib) is available in 50 mg, 100 mg, and 200 mg pills.

© 2022 Pfizer Inc.
All rights reserved.
Pfizer, PO Box 29387, Mission, KS 66201
Last Updated: January 2022 PP-ABR-USA-0056
Pfizer logo
Pfizer logo

Pfizer Dermatology Patient Access Interim Care Rx Program

TERMS AND CONDITIONS

×
Interim Care Rx is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for CIBINQO™ (abrocitinib). No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer. Not available to patients covered under Medicaid, Medicare or other federal or state healthcare programs, including any state prescription drug assistance programs and the Government Health Insurance Plan or for residents of Massachusetts, Michigan, Minnesota, Missouri, Ohio, or Rhode Island. Available up to a 30-day supply. Refills are subject to limitations. Interim Care Rx offer does not require, nor will be made contingent on, purchase requirements of any kind. Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification. Interim Care Rx can only be dispensed by the exclusive pharmacy and only after benefits investigation has been completed and a delay occurs in the prior authorization or appeals process. Offer good only in the U.S. and Puerto Rico. Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico. Continued eligibility for the program requires submission of two appeals within 180 days of enrollment. After 12 months of program enrollment, an updated prescription and benefits investigation is required to confirm continued eligibility. Additional eligibility criteria may apply. Contact Pfizer Dermatology Patient Access™ at 1-833-956-3376 for details.